Aimovig™

Generic Name: Erenumab
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20101267Migraine Prophylaxis1aA Phase I, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and Migraine Patients
20101268Migraine Patients1b

Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and in Migraine Patients

20120130Migraine1A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 334 in Healthy Japanese Subjects.
20120178Migraine Prevention2A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention.
20120295Chronic Migraine Prevention2A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention.
20120296Migraine Prevention3A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention.
20120297Migraine Prevention3A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
20140254Stable Angina2aA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina.
20140255Blood Pressure1Phase 1, Randomized, Parallel-Group, Double-Blind,Placebo-Controlled, Single-dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (Imitrex) in Healthy Subjects.
20140477Migraine1An Open Label Randomized Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavailability of 3 Different AMG 334 Treatments.
20150149Migraine1Single-Blind, Randomized, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Three 140 mg AMG 334 Subcutaneous Treatments in Healthy Subjects.
20150334Migraine1A Multi-center, Open-label, Pharmacokinetic Drug Interaction Study of AMG 334 and a Combined Oral Contraceptive in Healthy Female Subjects.
20120178/20130255Prevention of episodic migraine2Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
20130255 (Final Analysis)Prevention of chronic migraine2An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334